Marschik, T. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Datopotamab deruxtecan (Datroway®) for the treatment of unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. Fact Sheet Nr. 210.

Rothschedl, E. and Marschik, T. (2025): Blinatumomab (Blincyto®) monotherapy as part of consolidation therapy for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL). Fact Sheet Nr. 208.

Marschik, T. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Fact Sheet Nr. 212.